Shaji K Kumar

List of Publications by Year in Descending Order

1,055 papers	47,541 citations	104 h-index	190 g-index
1,178 ext. papers	57,124 ext. citations	5.3 avg, IF	7.28 L-index

#	Paper	IF	Citations
1055	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2022.. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 8-19	7.3	7
1054	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.. *Blood Cancer Journal* , **2022**, 12, 9	7	4
1053	Kidney Transplant Outcomes of Patients With Multiple Myeloma.. *Kidney International Reports*, **2022**, 7, 752-762	4.1	0
1052	A simple additive staging system for newly diagnosed multiple myeloma.. *Blood Cancer Journal*, **2022**, 12, 21	7	4
1051	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. *Leukemia*, **2022**,	10.7	2
1050	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. *Lancet Haematology,the*, **2022**, 9, e143-e161	14.6	6
1049	Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.. *Advances in Therapy*, **2022**, 1	4.1	1
1048	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.. *Blood Cancer Journal*, **2022**, 12, 39	7	1
1047	Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison.. *Leukemia and Lymphoma*, **2022**, 1-10	1.9	
1046	Current Approaches to Management of Newly Diagnosed Multiple Myeloma.. *American Journal of Hematology*, **2022**,	7.1	2
1045	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma.. *Oncology and Therapy*, **2022**, 1	2.7	0
1044	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**,	4.4	
1043	Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients.. *Blood Cancer Journal*, **2022**, 12, 53	7	0
1042	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.. *Therapeutic Advances in Hematology*, **2022**, 13, 20406207221082043	5.7	0
1041	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. *Blood Cancer Journal*, **2022**, 12, 59	7	0
1040	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. *Blood Cancer Journal*, **2022**, 12, 62	7	0
1039	Cutaneous manifestations of monoclonal gammopathy.. *Blood Cancer Journal*, **2022**, 12, 58	7	0

1038	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.. *Blood Cancer Journal*, **2022**, 12, 67	7	1
1037	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.. *Blood Cancer Journal*, **2022**, 12, 60	7	
1036	Financial toxicity in hematological malignancies: a systematic review.. *Blood Cancer Journal*, **2022**, 12, 74	7	0
1035	Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy.. *Frontiers in Oncology*, **2022**, 12, 859455	5.3	0
1034	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. *Leukemia and Lymphoma*, **2022**, 1-6	1.9	0
1033	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.. *JCO Oncology Practice*, **2022**, OP2100789	2.3	
1032	A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. *American Journal of Cancer Research*, **2021**, 11, 3285-3293	4.4	
1031	The mechanisms and therapeutic targets of ferroptosis in cancer. *Expert Opinion on Therapeutic Targets*, **2021**,	6.4	3
1030	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. *Blood*, **2021**, 138, 651-651	2.2	9
1029	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. *Blood Cancer Journal*, **2021**, 11, 186	7	1
1028	Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 1347-1350	7.3	
1027	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. *Leukemia*, **2021**,	10.7	3
1026	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. *American Journal of Hematology*, **2021**,	7.1	1
1025	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. *Transplantation and Cellular Therapy*, **2021**, 28, 83.e1-83.e1		1
1024	Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2021**, 138, 2735-2735	2.2	1
1023	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. *Bone Marrow Transplantation*, **2021**,	4.4	0
1022	Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.. *EClinicalMedicine*, **2021**, 42, 101225	11.3	0
1021	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. *Leukemia*, **2021**,	10.7	5

1020	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncology, The*, **2021**, 22, 1582-1596	21.7	19
1019	Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. *American Journal of Hematology*, **2021**,	7.1	7
1018	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. *Leukemia*, **2021**,	10.7	1
1017	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. *Bone Marrow Transplantation*, **2021**,	4.4	1
1016	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. *Blood Cancer Journal*, **2021**, 11, 45	7	5
1015	The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. *American Journal of Hematology*, **2021**, 96, 846-853	7.1	6
1014	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*, **2021**, 137, 3616-3628	2.2	16
1013	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. *Mayo Clinic Proceedings*, **2021**, 96, 677-687	6.4	4
1012	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. *Blood Cancer Journal*, **2021**, 11, 50	7	8
1011	Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. *Blood Advances*, **2021**, 5, 1797-1804	7.8	7
1010	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. *Lancet Oncology, The*, **2021**, 22, e105-e118	21.7	32
1009	Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 63	7	0
1008	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. *Blood Advances*, **2021**, 5, 2101-2105	7.8	5
1007	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. *American Journal of Hematology*, **2021**, 96, 690-697	7.1	2
1006	Current approaches to management of high-risk multiple myeloma. *American Journal of Hematology*, **2021**, 96, 854-871	7.1	8
1005	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. *Leukemia*, **2021**, 35, 3604-3607	10.7	4
1004	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. *American Journal of Hematology*, **2021**, 96, 945-953	7.1	2
1003	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. *Mayo Clinic Proceedings*, **2021**, 96, 1546-1577	6.4	8

1002	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. *Genes Chromosomes and Cancer*, **2021**, 60, 678-686	5	1
1001	Initial Therapeutic Approaches to Patients with Multiple Myeloma. *Advances in Therapy*, **2021**, 38, 3694-3711	4.1	4
1000	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. *Blood Cancer Journal*, **2021**, 11, 120	7	3
999	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 451-460.e2	2	2
998	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. *Transplantation and Cellular Therapy*, **2021**, 27, 589.e1-589.e6		2
997	Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE. *Blood*, **2021**,	2.2	12
996	Multiple Myeloma: From Baby Steps to Giant Strides. *JCO Oncology Practice*, **2021**, 17, 419-420	2.3	0
995	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. *Blood Advances*, **2021**, 5, 2753-2759	7.8	0
994	Decoding DNA methylation in epigenetics of multiple myeloma. *Blood Reviews*, **2021**, 51, 100872	11.1	3
993	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 274-277	4.4	0
992	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. *Blood*, **2021**, 137, 513-523	2.2	1
991	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. *Leukemia*, **2021**, 35, 18-30	10.7	29
990	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. *Kidney International*, **2021**, 99, 707-715	9.9	5
989	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. *American Journal of Hematology*, **2021**, 96, E5-E8	7.1	9
988	Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). *Leukemia*, **2021**, 35, 1797-1802	10.7	5
987	Lymphoma-like double-hit genetic abnormalities (and) in a case of non-secretory multiple myeloma. *Leukemia and Lymphoma*, **2021**, 62, 243-246	1.9	
986	Characterization and prognostic implication of delayed complete response in AL amyloidosis. *European Journal of Haematology*, **2021**, 106, 354-361	3.8	3
985	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. *European Journal of Haematology*, **2021**, 106, 433-436	3.8	0

984	Autologous stem cell transplantation for multiple myeloma patients aged ≥75 treated with novel agents. *Bone Marrow Transplantation*, **2021**, 56, 1144-1150	4.4	5
983	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2021**, 193, 380-385	4.5	9
982	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. *American Journal of Hematology*, **2021**, 96, 330-337	7.1	3
981	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. *Transplantation and Cellular Therapy*, **2021**, 27, 264.e1-264.e7		6
980	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. *Bone Marrow Transplantation*, **2021**, 56, 928-935	4.4	2
979	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. *Journal of Clinical Oncology*, **2021**, 39, 227-237	2.2	4
978	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5		
977	Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e48-e51	2	1
976	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. *Leukemia and Lymphoma*, **2021**, 62, 316-322	1.9	1
975	Systemic amyloidosis from A (AA) to T (ATTR): a review. *Journal of Internal Medicine*, **2021**, 289, 268-292	10.8	35
974	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. *Hematology*, **2021**, 26, 652-655	2.2	0
973	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. *Blood Advances*, **2021**, 5, 367-376	7.8	5
972	Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. *American Journal of Hematology*, **2021**, 96, 418-427	7.1	25
971	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. *Leukemia*, **2021**, 35, 1428-1437	10.7	4
970	Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. *American Journal of Hematology*, **2021**, 96, E157-E162	7.1	2
969	Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. *Blood Advances*, **2021**, 5, 1097-1101	7.8	11
968	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). *Blood Cancer Journal*, **2021**, 11, 26	7	3
967	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. *Blood Cancer Journal*, **2021**, 11, 24	7	24

966	Prognostic restaging after treatment initiation in patients with AL amyloidosis. *Blood Advances*, **2021**, 5, 1029-1036	7.8	3
965	Post-Transplant Maintenance Treatment Options in Multiple Myeloma. *Oncology and Therapy*, **2021**, 9, 69-88	2.7	0
964	Coagulation Abnormalities in Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2021**, 96, 377-387	6.4	3
963	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. *Leukemia and Lymphoma*, **2021**, 62, 3011-3018	1.9	0
962	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. *American Journal of Hematology*, **2021**, 96, 1131-1136	7.1	6
961	Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. *Clinical Cancer Research*, **2021**,	12.9	1
960	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. *Blood*, **2021**,	2.2	5
959	Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. *Leukemia and Lymphoma*, **2021**, 62, 3087-3097	1.9	0
958	The Prognostic Role of Structural Variants Identified by NGS and FISH in Multiple Myeloma. *Clinical Cancer Research*, **2021**,	12.9	5
957	Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *Journal of Clinical Oncology*, **2021**, 39, 2430-2442	2.2	18
956	Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based electronic health records from 2011 to 2019. *Cancer Medicine*, **2021**, 10, 5866-5877	4.8	5
955	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. *Cancer*, **2021**, 127, 4233-4239	6.4	2
954	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. *British Journal of Haematology*, **2021**, 195, 210-216	4.5	5
953	Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies. *Expert Review of Hematology*, **2021**, 1-16	2.8	0
952	Extramedullary disease in multiple myeloma. *Blood Cancer Journal*, **2021**, 11, 161	7	7
951	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, e710-e713	2	
950	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). *Blood Cancer Journal*, **2021**, 11, 158	7	1
949	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. *Transplantation and Cellular Therapy*, **2021**, 27, 770.e1-770.e7		0

948	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood Advances*, **2021**, 5, 3748-3759	7.8	11
947	Daratumumab for post-ASCT maintenance treatment of myeloma. *Lancet Oncology, The*, **2021**, 22, 1345-1347	11.7	
946	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. *American Journal of Hematology*, **2021**, 96, 446-454	7.1	3
945	Modulation of Apoptosis Pathways in the Biology and Treatment of Multiple Myeloma. *Touch Reviews in Oncology & Haematology*, **2021**, 17, 48		
944	Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. *Therapeutic Advances in Hematology*, **2021**, 12, 20406207211030369	5.7	0
943	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. *Blood Cancer Journal*, **2021**, 11, 196	7	3
942	In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. *Cancer & Metabolism*, **2020**, 8, 29	5.4	6
941	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. *Blood Cancer Journal*, **2020**, 10, 124	7	1
940	Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. *Blood*, **2020**, 136, 3033-3040	2.2	84
939	Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. *Lancet Haematology,the*, **2020**, 7, e704-e706	14.6	2
938	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. *Bone Marrow Transplantation*, **2020**, 55, 2132-2137	4.4	5
937	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1402-1405	4.7	2
936	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. *Blood Cancer Journal*, **2020**, 10, 52	7	4
935	BiTEing the Tumor. *Journal of Clinical Oncology*, **2020**, 38, 2077-2079	2.2	4
934	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. *Blood Cancer Journal*, **2020**, 10, 55	7	22
933	"Direct to Drug" screening as a precision medicine tool in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 54	7	8
932	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. *British Journal of Haematology*, **2020**, 190, 346-357	4.5	8
931	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. *Leukemia*, **2020**, 34, 3298-3309	10.7	23

930	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. *Mayo Clinic Proceedings*, **2020**, 95, 944-954	6.4	0
929	Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression. *Blood Cancer Discovery*, **2020**, 1, 68-81	7	13
928	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. *Bone Marrow Transplantation*, **2020**, 55, 1297-1304	4.4	3
927	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. *Blood Cancer Journal*, **2020**, 10, 39	7	1
926	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. *European Journal of Haematology*, **2020**, 105, 35-46	3.8	4
925	Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes. *Bone Marrow Transplantation*, **2020**, 55, 1879-1881	4.4	1
924	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. *Leukemia and Lymphoma*, **2020**, 61, 1752-1755	1.9	5
923	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. *American Journal of Hematology*, **2020**, 95, 637-642	7.1	6
922	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. *Journal of Molecular Diagnostics*, **2020**, 22, 679-684	5.1	6
921	N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression. *Leukemia*, **2020**, 34, 2749-2753	10.7	17
920	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. *Scientific Reports*, **2020**, 10, 10250	4.9	7
919	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. *Blood Advances*, **2020**, 4, 2789-2797	7.8	8
918	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 20	7	18
917	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. *British Journal of Haematology*, **2020**, 190, 249-261	4.5	6
916	Mass cytometry identifies expansion of double positive and exhausted T cell subsets in the tumour microenvironment of patients with POEMS syndrome. *British Journal of Haematology*, **2020**, 190, 79-83	4.5	0
915	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. *Blood Cancer Journal*, **2020**, 10, 4	7	12
914	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. *American Journal of Hematology*, **2020**, 95, 497-502	7.1	27
913	Role of imaging in multiple myeloma. *American Journal of Hematology*, **2020**, 95, 966-977	7.1	8

912	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. *American Journal of Hematology*, **2020**, 95, E222-E225	7.1	11
911	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 596-601	2	3
910	Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States. *Expert Review of Hematology*, **2020**, 13, 687-696	2.8	1
909	Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study. *Blood*, **2020**, 136, 24-26	2.2	17
908	Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 26-27	2.2	31
907	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. *Blood*, **2020**, 136, 36-37	2.2	3
906	Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2020**, 136, 28-29	2.2	25
905	Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. *Blood*, **2020**, 136, 43-44	2.2	34
904	Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM). *Blood*, **2020**, 136, 30-31	2.2	2
903	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. *Blood Advances*, **2020**, 4, 2236-2244	7.8	7
902	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. *Journal of Clinical Oncology*, **2020**, 38, 2380-2389	2.2	46
901	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. *Journal of Clinical Oncology*, **2020**, 38, 8509-8509	2.2	19
900	A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma.. *Journal of Clinical Oncology*, **2020**, 38, TPS8554-TPS8554	2.2	7
899	Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.. *Journal of Clinical Oncology*, **2020**, 38, LBA3-LBA3	2.2	22
898	Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?. *Clinical Hematology International*, **2020**, 2, 133-142	1.8	1
897	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 1685-1717	7.3	43
896	Quality of life (QOL), financial burden, and perception of care in patients enrolled on clinical trials (CTs).. *Journal of Clinical Oncology*, **2020**, 38, e19112-e19112	2.2	1
895	Ibrutinib monotherapy outside of clinical trial setting in Waldenstrm macroglobulinaemia: practice patterns, toxicities and outcomes. *British Journal of Haematology*, **2020**, 188, 394-403	4.5	23

894	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. *American Journal of Hematology*, **2020**, 95, E8-E10	7.1	5
893	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. *American Journal of Hematology*, **2020**, 95, 4-9	7.1	6
892	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2020**, 20, 53-56	2	5
891	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. *Cancer*, **2020**, 126, 1640-1650	6.4	8
890	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. *Journal of the National Cancer Institute*, **2020**, 112, 1021-1029	9.7	61
889	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. *American Journal of Hematology*, **2020**, 95, 310-315	7.1	16
888	Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. *American Journal of Hematology*, **2020**, 95, E60-E62	7.1	1
887	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. *American Journal of Hematology*, **2020**, 95, 274-281	7.1	18
886	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. *Leukemia*, **2020**, 34, 1373-1382	10.7	22
885	Revisiting complete response in light chain amyloidosis. *Leukemia*, **2020**, 34, 1472-1475	10.7	10
884	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. *Leukemia*, **2020**, 34, 1135-1143	10.7	19
883	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. *Cancer*, **2020**, 126, 5077-5087	6.4	16
882	Multiple myeloma current treatment algorithms. *Blood Cancer Journal*, **2020**, 10, 94	7	59
881	Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. *Hematology/Oncology Clinics of North America*, **2020**, 34, 1009-1026	3.1	2
880	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. *Cancer Medicine*, **2020**, 9, 8895-8901	4.8	1
879	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. *British Journal of Haematology*, **2020**, 191, 442-452	4.5	2
878	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 6581-6588	12.9	9
877	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). *Blood Cancer Journal*, **2020**, 10, 102	7	45

876	Predictors of short-term survival in Waldenström Macroglobulinemia. *Leukemia and Lymphoma*, **2020**, 61, 2975-2979	1.9	1
875	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. *American Journal of Hematology*, **2020**, 95, 1280-1287	7.1	10
874	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted - Authors' reply. *Lancet Oncology, The*, **2020**, 21, e541	21.7	
873	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. *Blood Advances*, **2020**, 4, 5449-5459	7.8	10
872	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. *Blood Advances*, **2020**, 4, 3509-3519	7.8	27
871	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 78	7	3
870	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. *Blood Cancer Journal*, **2020**, 10, 82	7	17
869	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncology, The*, **2020**, 21, 1630-1642	21.7	110
868	Immune-based therapies in the management of multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 84	7	18
867	Epigenetic silencing of long non-coding RNA in multiple myeloma: impact on prognosis and myeloma dissemination. *Cancer Cell International*, **2020**, 20, 403	6.4	7
866	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 1317-1330	21.7	76
865	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. *Blood Cancer Journal*, **2020**, 10, 87	7	7
864	Free Light Chain Assay Drift: Potential for Misdiagnosis?. *journal of applied laboratory medicine, The*, **2020**, 5, 1411-1413	2	2
863	Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma. *American Journal of Hematology*, **2020**, 95, 1486-1494	7.1	11
862	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2020**, 27, 13-16	2.7	21
861	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. *Journal of Clinical Oncology*, **2020**, 38, 1126-1137	2.2	88
860	MYC dysregulation in the progression of multiple myeloma. *Leukemia*, **2020**, 34, 322-326	10.7	56
859	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. *Leukemia*, **2020**, 34, 3338-3347	10.7	15

858	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. *Blood Advances*, **2020**, 4, 322-326	7.8	4
857	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. *Blood Cancer Journal*, **2020**, 10, 41	7	16
856	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. *Cancer*, **2020**, 127, 82-92	6.4	3
855	Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. *Blood Cancer Journal*, **2019**, 9, 72	7	21
854	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. *Leukemia*, **2019**, 33, 1736-1746	10.7	29
853	The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. *Leukemia*, **2019**, 33, 863-883	10.7	26
852	Comparative analysis of staging systems in AL amyloidosis. *Leukemia*, **2019**, 33, 811-814	10.7	15
851	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. *American Journal of Hematology*, **2019**, 94, E117-E120	7.1	6
850	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. *Lancet Oncology, The*, **2019**, 20, e302-e312	21.7	166
849	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. *New England Journal of Medicine*, **2019**, 380, 2104-2115	59.2	435
848	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, **2019**, 54, 2039-2050	4.4	6
847	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. *Blood Cancer Journal*, **2019**, 9, 49	7	4
846	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2019**, 60, 2960-2967	1.9	2
845	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1520-1525	4.7	6
844	The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. *Leukemia*, **2019**, 33, 2924-2933	10.7	23
843	Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m vs. twice-weekly 27 mg/m carfilzomib (randomized A.R.R.O.W. study). *Leukemia*, **2019**, 33, 2934-2946	10.7	13
842	Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin. *Journal of Clinical Oncology*, **2019**, 37, 171-173	2.2	18
841	Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. *British Journal of Haematology*, **2019**, 185, 701-707	4.5	10

840	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. *Haematologica*, **2019**, 104, 2061-2074	6.6	22
839	Natural history of multiple myeloma with de novo del(17p). *Blood Cancer Journal*, **2019**, 9, 32	7	22
838	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*, **2019**, 33, 2266-2275	10.7	188
837	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. *Blood Cancer Journal*, **2019**, 9, 20	7	6
836	Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. *Bone Marrow Transplantation*, **2019**, 54, 1775-1779	4.4	5
835	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. *European Journal of Haematology*, **2019**, 102, 494-503	3.8	8
834	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. *American Journal of Hematology*, **2019**, 94, 751-756	7.1	6
833	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *Journal of Clinical Oncology*, **2019**, 37, 1228-1263	2.2	104
832	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. *Mayo Clinic Proceedings*, **2019**, 94, 465-471	6.4	47
831	Substratification of patients with newly diagnosed standard-risk multiple myeloma. *British Journal of Haematology*, **2019**, 185, 254-260	4.5	8
830	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. *Leukemia*, **2019**, 33, 1268-1272	10.7	4
829	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, **2019**, 54, 587-594	4.4	7
828	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. *Bone Marrow Transplantation*, **2019**, 54, 442-447	4.4	5
827	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone Marrow Transplantation*, **2019**, 54, 353-367	4.4	51
826	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. *Leukemia and Lymphoma*, **2019**, 60, 163-171	1.9	8
825	Time Horizons in Cost Analyses. *JAMA - Journal of the American Medical Association*, **2019**, 322, 582-583	27.4	3
824	Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. *Annals of Oncology*, **2019**, 30, 1647-1652	10.3	6
823	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. *British Journal of Haematology*, **2019**, 187, 588-594	4.5	26

822	Surrogate endpoints in randomised controlled trials: a reality check. *Lancet, The*, **2019**, 394, 281-283	40	16
821	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 101-102	2.7	4
820	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. *Blood Advances*, **2019**, 3, 1226-1229	7.8	3
819	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. *Cancer*, **2019**, 125, 3574-3581	6.4	3
818	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. *American Journal of Hematology*, **2019**, 94, 1020-1026	7.1	25
817	Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. *PET Clinics*, **2019**, 14, 391-403	2.2	5
816	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. *American Journal of Hematology*, **2019**, 94, 1066-1071	7.1	9
815	A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e31	2	16
814	Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia. *Blood*, **2019**, 134, 1875-1875	2.2	18
813	Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. *Blood*, **2019**, 134, 926-926	2.2	10
812	Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).. *Journal of Clinical Oncology*, **2019**, 37, 6594-6594	2.2	4
811	Rituximab-based maintenance therapy in Waldenstr□m macroglobulinemia: A case control study.. *Journal of Clinical Oncology*, **2019**, 37, 7559-7559	2.2	6
810	E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.. *Journal of Clinical Oncology*, **2019**, 37, 8001-8001	2.2	13
809	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. *Journal of Clinical Oncology*, **2019**, 37, 8039-8039	2.2	22
808	NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 1154-1165	7.3	73
807	Early Intervention in Smoldering Myeloma. *Oncology & Hematology Review*, **2019**, 15, 14	0.1	
806	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. *Mayo Clinic Proceedings*, **2019**, 94, 455-464	6.4	13
805	Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.. *Journal of Clinical Oncology*, **2019**, 37, e18356-e18356	2.2	

804	Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study.. *Journal of Clinical Oncology*, **2019**, 37, 8027-8027	2.2	0
803	Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. *Blood*, **2019**, 134, 3160-3160	2.2	1
802	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. *American Journal of Hematology*, **2019**, 94, E141-E143	7.1	13
801	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. *Leukemia*, **2019**, 33, 1273-1277	10.7	7
800	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. *Mayo Clinic Proceedings*, **2019**, 94, 472-483	6.4	33
799	Targeted Management Strategies in Multiple Myeloma. *Cancer Journal (Sudbury, Mass)*, **2019**, 25, 59-64	2.2	4
798	Impact of acquired del(17p) in multiple myeloma. *Blood Advances*, **2019**, 3, 1930-1938	7.8	20
797	Cell cycle regulation and hematologic malignancies.. *Blood Science*, **2019**, 1, 34-43	0.9	8
796	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. *Blood Advances*, **2019**, 3, 744-750	7.8	15
795	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. *Blood Cancer Journal*, **2019**, 9, 103	7	18
794	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. *Blood Cancer Journal*, **2019**, 9, 102	7	27
793	Stem-cell transplantation in multiple myeloma: how far have we come?. *Therapeutic Advances in Hematology*, **2019**, 10, 2040620719888111	5.7	7
792	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. *HemaSphere*, **2019**, 3, 616	0.3	0
791	Daratumumab in untreated newly diagnosed multiple myeloma. *Therapeutic Advances in Hematology*, **2019**, 10, 2040620719894871	5.7	14
790	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. *Leukemia*, **2019**, 33, 499-507	10.7	4
789	Revised International Staging System Is Predictive and Prognostic for Early Relapse (. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 683-688	4.7	12
788	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. *Blood*, **2019**, 133, 652-659	2.2	27
787	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. *American Journal of Hematology*, **2019**, 94, 424-430	7.1	5

786	Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e108-e111	4.7	11
785	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. *Blood*, **2019**, 133, 763-766	2.2	20
784	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 1077-1081	4.4	3
783	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *European Journal of Cancer*, **2019**, 106, 89-98	7.5	14
782	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. *British Journal of Haematology*, **2019**, 184, 536-546	4.5	12
781	Molecular signatures of multiple myeloma progression through single cell RNA-Seq. *Blood Cancer Journal*, **2019**, 9, 2	7	37
780	Primary systemic amyloidosis in patients with Waldenstrm macroglobulinemia. *Leukemia*, **2019**, 33, 790-794	10.7	16
779	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. *Leukemia*, **2019**, 33, 730-738	10.7	11
778	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. *Leukemia*, **2019**, 33, 527-531	10.7	30
777	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*, **2019**, 33, 531-536	10.7	60
776	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2019**, 94, 306-311	7.1	9
775	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. *Leukemia*, **2018**, 32, 1421-1426	10.7	5
774	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia*, **2018**, 32, 1567-1574	10.7	31
773	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. *Leukemia*, **2018**, 32, 2240-2249	10.7	49
772	Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. *Haematologica*, **2018**, 103, 1229-1234	6.6	8
771	Fifty-Year Incidence of Waldenstrm Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. *Mayo Clinic Proceedings*, **2018**, 93, 739-746	6.4	16
770	The multiple myelomas - current concepts in cytogenetic classification and therapy. *Nature Reviews Clinical Oncology*, **2018**, 15, 409-421	19.4	121
769	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 889-894	7.1	8

768	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2127-2132	4.7	12
767	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrm macroglobulinemia. *Annals of Hematology*, **2018**, 97, 1417-1425	3	43
766	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1546-1553	4.7	19
765	Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. *Leukemia* , **2018**, 32, 1414-1420	10.7	9
764	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. *Leukemia*, **2018**, 32, 1811-1815	10.7	18
763	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. *Leukemia*, **2018**, 32, 1243-1246	10.7	12
762	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. *New England Journal of Medicine*, **2018**, 378, 241-249	59.2	216
761	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. *Bone Marrow Transplantation*, **2018**, 53, 326-333	4.4	4
760	Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. *Leukemia*, **2018**, 32, 986-995	10.7	41
759	Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. *Mayo Clinic Proceedings*, **2018**, 93, 56-58	6.4	12
758	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. *Leukemia and Lymphoma*, **2018**, 59, 2524-2534	1.9	36
757	Reply to Castillo et al. *American Journal of Hematology*, **2018**, 93, E71-E73	7.1	2
756	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 11-20	7.3	86
755	The evolution of stem-cell transplantation in multiple myeloma. *Therapeutic Advances in Hematology*, **2018**, 9, 123-133	5.7	21
754	Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. *Nature Communications*, **2018**, 9, 1691	17.4	103
753	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. *British Journal of Haematology*, **2018**, 182, 71-77	4.5	9
752	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 86-92	2.7	40
751	Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. *Blood Cancer Journal*, **2018**, 8, 26	7	68

750	Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. *Leukemia and Lymphoma*, **2018**, 59, 288-299	1.9	9
749	Natural history of t(11;14) multiple myeloma. *Leukemia*, **2018**, 32, 131-138	10.7	43
748	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. *American Journal of Hematology*, **2018**, 93, 179-186	7.1	29
747	MYD88 mutation status does not impact overall survival in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 187-194	7.1	45
746	Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). *European Journal of Haematology*, **2018**, 100, 215-217	3.8	40
745	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). *American Journal of Hematology*, **2018**, 93, 17-22	7.1	9
744	Minimal residual disease analysis in myeloma - when, why and where. *Leukemia and Lymphoma*, **2018**, 59, 1772-1784	1.9	14
743	Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. *Leukemia*, **2018**, 32, 719-728	10.7	12
742	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. *Leukemia*, **2018**, 32, 712-718	10.7	20
741	Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. *Leukemia*, **2018**, 32, 729-735	10.7	36
740	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2157-2159	4.7	3
739	ARNT/HIF-1links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. *Cancer Medicine*, **2018**, 7, 3899-3911	4.8	15
738	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 70	7	11
737	Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. *American Journal of Hematology*, **2018**, 93, 1207-1210	7.1	1
736	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. *Circulation: Cardiovascular Imaging*, **2018**, 11, e006588	3.9	31
735	Predictors of symptomatic hyperviscosity in Waldenstrm macroglobulinemia. *American Journal of Hematology*, **2018**, 93, 1384-1393	7.1	15
734	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2443-2449	4.7	8
733	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer Journal*, **2018**, 8, 59	7	115

732	Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. *JCI Insight*, **2018**, 3,	9.9	23
731	Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA). *Blood*, **2018**, 132, LBA-2-LBA-2	2.2	25
730	The Lysine-Specific Demethylase KDM4A/JMJD2A Acts As a Tumor Suppressor in Multiple Myeloma. *Blood*, **2018**, 132, 191-191	2.2	1
729	Natural History of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody-Based Treatment. *Blood*, **2018**, 132, 3233-3233	2.2	5
728	Mass Cytometry Identifies Immunomic Shifts in the Bone Marrow Microenvironment of Multiple Myeloma and Light Chain Amyloidosis after Standard of Care First Line Therapies. *Blood*, **2018**, 132, 1879-1879	2.2	1
727	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 304-304	2.2	8
726	Natural History of Patients with Multiple Myeloma Refractory to Elotuzumab and Outcomes of Subsequent Therapy with Anti-CD38 Monoclonal Antibodies. *Blood*, **2018**, 132, 3303-3303	2.2	1
725	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. *Blood*, **2018**, 132, 2015-2015	2.2	7
724	Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 3541-3541	2.2	1
723	Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2018**, 132, 303-303	2.2	14
722	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. *Blood*, **2018**, 132, 4460-4460	2.2	0
721	Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, 8004-8004	2.2	14
720	Daratumumab-based therapies in patients with AL amyloidosis.. *Journal of Clinical Oncology*, **2018**, 36, 8053-8053	2.2	2
719	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. *PLoS Genetics*, **2018**, 14, e1007111	6	20
718	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. *Oncotarget*, **2018**, 9, 34582-34594	3.3	3
717	High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy?. *Clinical Nephrology*, **2018**, 89, 291-299	2.1	3
716	Personalizing MM Treatment: Gaps in Current Knowledge **2018**, 169-178		
715	Early Intervention in Multiple MyelomaExploring New Frontiers. *Oncology & Hematology Review*, **2018**, 14, 12	0.1	

714	Tandem high-dose chemotherapy and autologous hematopoietic stem cell transplantation (SCT) compared to single SCT for relapsed/refractory germ cell tumors (GCT).. *Journal of Clinical Oncology*, **2018**, 36, 572-572	2.2	
713	Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2018**, 36, 8023-8023	2.2	
712	Predictors of disease progression in smoldering Waldenstrm macroglobulinemia.. *Journal of Clinical Oncology*, **2018**, 36, 7571-7571	2.2	
711	Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2018**, 36, e20049-e20049	2.2	
710	Comparative Analysis of Staging Systems in AL Amyloidosis. *Blood*, **2018**, 132, 3228-3228	2.2	
709	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 622-622	2.2	
708	Genomic Abnormalities Among African Individuals with Monoclonal Gammopathies Using Calculated Ancestry. *Blood*, **2018**, 132, 4458-4458	2.2	
707	Early Prediction of Treatment Response in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3159-3159	2.2	
706	Prognostic Significance of Early Immune Reconstitution in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 3158-3158	2.2	
705	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. *Blood*, **2018**, 132, 4449-4449	2.2	
704	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. *Blood*, **2018**, 132, 2147-2147	2.2	
703	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. *Blood*, **2018**, 132, 3226-3226	2.2	
702	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. *Blood*, **2018**, 132, 1606-1606	2.2	1
701	Expected Survival in Patients with Smoldering Multiple Myeloma and Multiple Myeloma. *Blood*, **2018**, 132, 4497-4497	2.2	
700	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). *Blood*, **2018**, 132, 4502-4502	2.2	
699	Development of Thrombocytopenia and Survival Outcomes in Newly Diagnosed Multiple Myeloma. *Blood*, **2018**, 132, 1902-1902	2.2	
698	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. *Blood*, **2018**, 132, 5594-5594	2.2	
697	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. *Blood*, **2018**, 132, 3227-3227	2.2	

696	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). *Blood*, **2018**, 132, 3268-3268	2.2	
695	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. *Blood*, **2018**, 132, 4501-4501	2.2	
694	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). *Blood*, **2018**, 132, 5664-5664	2.2	
693	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. *Blood*, **2018**, 132, 2884-2884	2.2	1
692	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. *Blood*, **2018**, 132, 3160-3160	2.2	2
691	Prognosis of Patients with Waldenstrm Macroglobulinemia: A Simplified Model. *Blood*, **2018**, 132, 4152-4152	2.2	1
690	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. *Blood*, **2018**, 132, 3253-3253	2.2	
689	Patient-Reported Outcome Driven Case Management System for Hematology a Prospective Study. *Blood*, **2018**, 132, 719-719	2.2	
688	Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. *Leukemia*, **2018**, 32, 252-262	10.7	171
687	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. *Bone Marrow Transplantation*, **2018**, 53, 155-161	4.4	3
686	Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. *Journal of Clinical Oncology*, **2018**, 36, 1323-1329	2.2	68
685	Monoclonal Antibodies for Myeloma: Make It Easy!. *Journal of Oncology Practice*, **2018**, 14, 423-424	3.1	
684	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 106	7	13
683	Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. *Blood Cancer Journal*, **2018**, 8, 109	7	97
682	Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. *Blood Cancer Journal*, **2018**, 8, 123	7	47
681	Ixazomib for the treatment of multiple myeloma. *Expert Opinion on Pharmacotherapy*, **2018**, 19, 1949-1968	4	32
680	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer Journal*, **2018**, 8, 116	7	38
679	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. *Blood Cancer Journal*, **2018**, 8, 125	7	17

678	Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. *Nature Communications*, **2018**, 9, 4832	17.4	78
677	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry. *Blood Cancer Journal*, **2018**, 8, 96	7	29
676	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2018**, 93, 1518-1523	7.1	15
675	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. *Blood Advances*, **2018**, 2, 769-776	7.8	16
674	Timing of treatment of smoldering myeloma: delay until progression. *Blood Advances*, **2018**, 2, 3050-3053	7.8	3
673	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. *Blood Advances*, **2018**, 2, 3149-3154	7.8	17
672	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. *Leukemia*, **2018**, 32, 2083-2085	10.7	2
671	Management of Multiple Myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 624-627	7.3	9
670	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2360-2364	4.7	13
669	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. *Leukemia*, **2017**, 31, 92-99	10.7	29
668	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, **2017**, 58, 308-315	1.9	12
667	Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. *Indian Journal of Hematology and Blood Transfusion*, **2017**, 33, 15-21	0.7	9
666	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 598-605	4.7	32
665	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. *American Journal of Hematology*, **2017**, 92, 467-472	7.1	9
664	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. *Annals of Medicine*, **2017**, 49, 545-551	1.5	27
663	Treating Multiple Myeloma Patients With Oral Therapies. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 243-251	2	21
662	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e528	7	23
661	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). *Targeted Oncology*, **2017**, 12, 201-209	5	18

660	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. *American Journal of Hematology*, **2017**, 92, 435-440	7.1	10
659	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. *European Journal of Haematology*, **2017**, 98, 563-568	3.8	6
658	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. *Blood*, **2017**, 129, 82-87	2.2	41
657	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. *Blood*, **2017**, 129, 2111-2119	2.2	181
656	Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. *Indian Journal of Hematology and Blood Transfusion*, **2017**, 33, 153-158	0.7	
655	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. *Clinical Cancer Research*, **2017**, 23, 3980-3993	12.9	51
654	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. *Bone Marrow Transplantation*, **2017**, 52, 1126-1132	4.4	20
653	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *British Journal of Haematology*, **2017**, 178, 571-582	4.5	39
652	Outcome of very young (Ø40 years) patients with immunoglobulin light chain (AL) amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 50-51	2.7	4
651	E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. *Leukemia*, **2017**, 31, 2642-2651	10.7	23
650	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 44-45	2.7	1
649	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. *Journal of Internal Medicine*, **2017**, 281, 611-619	10.8	10
648	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. *Leukemia*, **2017**, 31, 1562-1569	10.7	70
647	Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia*, **2017**, 31, 2443-2448	10.7	169
646	Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e569	7	6
645	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. *British Journal of Haematology*, **2017**, 178, 756-763	4.5	14
644	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 230-269	7.3	142
643	New Treatment Options for the Management of Multiple Myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 709-712	7.3	4

642	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. *American Journal of Hematology*, **2017**, 92, E507-E512	7.1	3
641	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. *American Journal of Hematology*, **2017**, 92, 668-673	7.1	46
640	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncology, The*, **2017**, 18, e206-e217	21.7	275
639	Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. *Mayo Clinic Proceedings*, **2017**, 92, 578-598	6.4	88
638	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. *American Journal of Hematology*, **2017**, 92, 549-554	7.1	18
637	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. *JAMA Oncology*, **2017**, 3, 1257-1265	13.4	82
636	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. *Blood*, **2017**, 130, 2401-2409	2.2	277
635	Identifying the Right Patient for Bcl2 Inhibition in Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, S144-S145	2	
634	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. *Blood*, **2017**, 130, 2610-2618	2.2	69
633	Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 518-524	3.1	20
632	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. *Mayo Clinic Proceedings*, **2017**, 92, 908-917	6.4	43
631	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. *Targeted Oncology*, **2017**, 12, 643-654	5	16
630	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. *Blood*, **2017**, 130, 1578-1584	2.2	15
629	Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. *Blood*, **2017**, 130, 2392-2400	2.2	182
628	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. *Bone Marrow Transplantation*, **2017**, 52, 1616-1622	4.4	28
627	Checking in: T cells against multiple myeloma. *Blood*, **2017**, 130, 1175-1176	2.2	3
626	Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e600	7	43
625	A phase 1 trial of Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. *Bone Marrow Transplantation*, **2017**, 52, 1372-1377	4.4	10

624	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. *British Journal of Haematology*, **2017**, 178, 888-895	4.5	14
623	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. *Haematologica*, **2017**, 102, 1439-1445	6.6	19
622	Multiple myeloma. *Nature Reviews Disease Primers*, **2017**, 3, 17046	51.1	484
621	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. *British Journal of Haematology*, **2017**, 179, 98-105	4.5	12
620	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. *American Journal of Hematology*, **2017**, 92, 1146-1155	7.1	22
619	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2017**, 24, 183-188	2.7	1
618	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 555-562	2	18
617	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. *Blood*, **2017**, 130, 1198-1204	2.2	46
616	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. *Blood Cancer Journal*, **2017**, 7, e581	7	27
615	Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. *American Journal of Hematology*, **2017**, 92, 220-221	7.1	21
614	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. *Bone Marrow Transplantation*, **2017**, 52, 34-40	4.4	20
613	Natural history of amyloidosis isolated to fat and bone marrow aspirate. *British Journal of Haematology*, **2017**, 179, 170-172	4.5	7
612	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. *American Journal of Hematology*, **2017**, 92, 50-55	7.1	30
611	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. *Leukemia*, **2017**, 31, 130-135	10.7	46
610	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 269-277	4.7	15
609	Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. *Blood Cancer Journal*, **2017**, 7, e618	7	43
608	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. *Leukemia*, **2017**,	10.7	6
607	Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. *Blood Advances*, **2017**, 1, 282-287	7.8	164

606	New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. *Journal of Blood Medicine*, **2017**, 8, 107-121	2.3	17
605	NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).. *Journal of Clinical Oncology*, **2017**, 35, 2023-2023	2.2	4
604	Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.. *Journal of Clinical Oncology*, **2017**, 35, 8006-8006	2.2	16
603	Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2017**, 35, 8038-8038	2.2	1
602	Factors predicting organ response in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8048-8048	2.2	1
601	Nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone, for relapsed/refractory multiple myeloma: 2 cohorts of the phase 1 CheckMate 039 safety study.. *Journal of Clinical Oncology*, **2017**, 35, TPS3102-TPS3102	2.2	2
600	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. *Blood*, **2017**, 130, 902-902	2.2	3
599	Plasma Cell Leukemia **2017**, 1-16		
598	Natural history of t(11;14) multiple myeloma (MM).. *Journal of Clinical Oncology*, **2017**, 35, 8014-8014	2.2	0
597	The use of proteasome inhibitors among patients with POEMS syndrome.. *Journal of Clinical Oncology*, **2017**, 35, e19530-e19530	2.2	
596	Impact of metformin use in the outcomes of multiple myeloma patients post stem cell transplant.. *Journal of Clinical Oncology*, **2017**, 35, 8034-8034	2.2	
595	Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8049-8049	2.2	
594	Risk stratification by detection of clonal circulating plasma cells (CPCs) by multi-parametric flow cytometry (MFC) in light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2017**, 35, 8047-8047	2.2	
593	Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. *Journal of Clinical Oncology*, **2017**, 35, 8020-8020	2.2	
592	Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. *Journal of Clinical Oncology*, **2017**, 35, e19532-e19532	2.2	
591	The impact of body mass index on the risk of early progression of smoldering multiple myeloma to symptomatic myeloma.. *Journal of Clinical Oncology*, **2017**, 35, 8032-8032	2.2	
590	Treatment approaches and outcomes in extramedullary plasmacytomas.. *Journal of Clinical Oncology*, **2017**, 35, 8050-8050	2.2	
589	Plasmacytoma□Current Approach to Diagnosis and Management **2017**, 17-39		1

588	Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. *Leukemia*, **2016**, 30, 633-9	10.7	42
587	Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma. *Leukemia*, **2016**, 30, 995-8	10.7	10
586	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 1129-1134	7.1	42
585	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncology, The*, **2016**, 17, e328-e346	21.7	1155
584	IAP antagonists induce anti-tumor immunity in multiple myeloma. *Nature Medicine*, **2016**, 22, 1411-1420	50.5	99
583	Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. *Blood Cancer Journal*, **2016**, 6, e397	7	38
582	Clinical characteristics and outcomes in biclonal gammopathies. *American Journal of Hematology*, **2016**, 91, 473-5	7.1	20
581	Gene signature combinations improve prognostic stratification of multiple myeloma patients. *Leukemia*, **2016**, 30, 1071-8	10.7	43
580	Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. *Leukemia*, **2016**, 30, 1079-85	10.7	24
579	Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. *Blood Cancer Journal*, **2016**, 6, e401	7	21
578	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. *Nephrology Dialysis Transplantation*, **2016**, 31, 1284-9	4.3	21
577	Multiple Myeloma: Diagnosis and Treatment. *Mayo Clinic Proceedings*, **2016**, 91, 101-19	6.4	290
576	Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. *Leukemia*, **2016**, 30, 1005-17	10.7	159
575	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. *Leukemia*, **2016**, 30, 1094-102	10.7	42
574	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. *Blood*, **2016**, 128, 197-197	2.2	7
573	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 2082-2082	2.2	1
572	Using Continuing Medical Education to Promote Shared Decision-Making in Patients Diagnosed with Multiple Myeloma. *Blood*, **2016**, 128, 2388-2388	2.2	2
571	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 243-243	2.2	3

570	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). *Blood*, **2016**, 128, 2968-2968	2.2	3
569	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2972-2972	2.2	2
568	Clinical Features and Outcomes of Plasmacytoma in the United States: Analysis Using the National Cancer Data Base. *Blood*, **2016**, 128, 3249-3249	2.2	1
567	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. *Blood*, **2016**, 128, 3272-3272	2.2	1
566	A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics. *Blood*, **2016**, 128, 3316-3316	2.2	8
565	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 3317-3317	2.2	3
564	Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*, **2016**, 128, 3327-3327	2.2	8
563	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. *Blood*, **2016**, 128, 3337-3337	2.2	5
562	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. *Blood*, **2016**, 128, 3444-3444	2.2	1
561	Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma. *Blood*, **2016**, 128, 4517-4517	2.2	2
560	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. *Blood*, **2016**, 128, 4627-4627	2.2	1
559	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. *Blood*, **2016**, 128, 488-488	2.2	21
558	Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. *Blood*, **2016**, 128, 975-975	2.2	18
557	Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).. *Journal of Clinical Oncology*, **2016**, 34, 8002-8002	2.2	3
556	Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM).. *Journal of Clinical Oncology*, **2016**, 34, 8004-8004	2.2	1
555	Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).. *Journal of Clinical Oncology*, **2016**, 34, 8005-8005	2.2	26
554	Importance of pharmacovigilance in the era of small molecules: Role of pharmacist consultation with ixazomib (IXA) in multiple myeloma (MM).. *Journal of Clinical Oncology*, **2016**, 34, 8058-8058	2.2	4
553	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. *Oncotarget*, **2016**, 7, 56253-56265	3.3	14

552	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. *Journal of Clinical Oncology*, **2016**, 34, 8033-8033	2.2	
551	Changes in serum alkaline phosphatase levels to predict response to ixazomib-based therapy in patients with newly diagnosed multiple myeloma.. *Journal of Clinical Oncology*, **2016**, 34, 8053-8053	2.2	
550	Dexamethasone, rituximab and cyclophosphamide (DRC) in relapsed/refractory (R/R) and treatment naïve (TN) Waldenström macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2016**, 34, 7552-7552	2.2	1
549	Beyond maximum grade: A novel method to assess toxicity over time in clinical trials of targeted therapy in lymphoma.. *Journal of Clinical Oncology*, **2016**, 34, 7546-7546	2.2	
548	Type 1 monoclonal cryoglobulinemia: Clinical presentation and outcomes.. *Journal of Clinical Oncology*, **2016**, 34, 8062-8062	2.2	
547	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. *Blood*, **2016**, 128, 4425-4425	2.2	
546	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. *Blood*, **2016**, 128, 2960-2960	2.2	
545	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2016**, 128, 5615-5615	2.2	
544	A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. *Blood*, **2016**, 128, 996-996	2.2	
543	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273	2.2	
542	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. *Blood*, **2016**, 128, 1810-1810	2.2	
541	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. *Blood*, **2016**, 128, 3306-3306	2.2	
540	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. *Blood*, **2016**, 128, 1194-1194	2.2	
539	Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool. *Blood*, **2016**, 128, 2379-2379	2.2	
538	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. *Blood*, **2016**, 128, 3338-3338	2.2	
537	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. *Blood*, **2016**, 128, 3255-3255	2.2	
536	Outcome of Very Young (≤40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. *Blood*, **2016**, 128, 5576-5576	2.2	
535	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. *Blood*, **2016**, 128, 2187-2187	2.2	

534	Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma. *Blood*, **2016**, 128, 2267-2267	2.2	
533	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. *Clinical Pharmacology: Advances and Applications*, **2016**, 8, 35-44	1.5	21
532	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. *Blood Coagulation and Fibrinolysis*, **2016**, 27, 101-8	1	5
531	Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma. *Cancer Journal (Sudbury, Mass)*, **2016**, 22, 7-11	2.2	0
530	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. *Cancer*, **2016**, 122, 2197-205	6.4	28
529	Autologous stem cell transplant for multiple myeloma patients 70 years or older. *Bone Marrow Transplantation*, **2016**, 51, 1449-1455	4.4	37
528	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. *American Journal of Hematology*, **2016**, 91, 984-8	7.1	37
527	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. *Blood*, **2016**, 128, 2415-2422	2.2	42
526	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. *Blood Cancer Journal*, **2016**, 6, e454	7	42
525	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. *Blood Cancer Journal*, **2016**, 6, e512	7	28
524	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. *Haematologica*, **2016**, 101, 1102-9	6.6	9
523	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 389-400	7.3	44
522	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. *Leukemia Research*, **2016**, 44, 32-9	2.7	13
521	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 447-52	2	19
520	Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. *Leukemia*, **2016**, 30, 2208-2213	10.7	55
519	Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. *Bone Marrow Transplantation*, **2016**, 51, 1156-8	4.4	14
518	Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. *Leukemia and Lymphoma*, **2016**, 57, 2827-2832	1.9	38
517	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. *New England Journal of Medicine*, **2016**, 374, 1621-34	59.2	684

516	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1609-1618	4	13
515	Myelomatous Involvement of the Central Nervous System. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 644-654	2	29
514	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. *Mayo Clinic Proceedings*, **2016**, 91, 1354-1361	6.4	30
513	Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. *Cancer Treatment and Research*, **2016**, 169, 145-167	3.5	6
512	New investigational drugs with single-agent activity in multiple myeloma. *Blood Cancer Journal*, **2016**, 6, e451	7	54
511	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. *American Journal of Hematology*, **2016**, 91, 1123-1128	7.1	52
510	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1893-1899	4.7	19
509	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. *American Journal of Hematology*, **2016**, 91, 585-9	7.1	40
508	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. *British Journal of Haematology*, **2016**, 174, 323-5	4.5	21
507	Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2016**, 91, 101-8	7.1	16
506	Clinical Course and Prognosis of Non-Secretory Multiple Myeloma. *European Journal of Haematology*, **2015**,	3.8	4
505	Clinical course and prognosis of non-secretory multiple myeloma. *European Journal of Haematology* , **2015**, 95, 57-64	3.8	33
504	Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. *Mayo Clinic Proceedings*, **2015**, 90, 587-96	6.4	70
503	Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. *Mayo Clinic Proceedings*, **2015**, 90, 1054-81	6.4	81
502	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *Journal of Clinical Oncology*, **2015**, 33, 2863-9	2.2	976
501	Early mortality in multiple myeloma. *Leukemia*, **2015**, 29, 1616-8	10.7	22
500	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nature Communications*, **2015**, 6, 7539	17.4	31
499	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leukemia and Lymphoma*, **2015**, 56, 1723-6	1.9	14

498	Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. *Leukemia*, **2015**, 29, 1195-201	10.7	29
497	Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 349-357.e2	2	8
496	Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. *Leukemia*, **2015**, 29, 2033-8	10.7	22
495	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. *Future Oncology*, **2015**, 11, 1153-68	3.6	23
494	Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2015**, 50, 1513-8	4.4	30
493	Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. *Blood Cancer Journal*, **2015**, 5, e310	7	51
492	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 2039-2051	4.7	114
491	Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. *Blood Cancer Journal*, **2015**, 5, e294	7	4
490	Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. *American Journal of Hematology*, **2015**, 90, 524-8	7.1	25
489	Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. *Blood Cancer Journal*, **2015**, 5, e338	7	62
488	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. *Journal of Clinical Oncology*, **2015**, 33, 3741-9	2.2	130
487	Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 335-41	4.7	50
486	Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. *Blood*, **2015**, 125, 443-8	2.2	148
485	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood*, **2015**, 125, 2068-74	2.2	426
484	Blind men and an elephant. *Blood*, **2015**, 125, 745-7	2.2	1
483	Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. *Cancer Control*, **2015**, 22, 87-94	2.2	5
482	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. *Rare Cancers and Therapy*, **2015**, 3, 47-68		11
481	Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. *American Journal of Hematology*, **2015**, 90, 1106-10	7.1	14

480	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. *American Journal of Hematology*, **2015**, 90, 888-91	7.1	14
479	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. *American Journal of Hematology*, **2015**, 90, 981-5	7.1	28
478	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. *Blood Cancer Journal*, **2015**, 5, e296	7	73
477	Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. *Leukemia and Lymphoma*, **2015**, 56, 3357-64	1.9	28
476	Bisphosphonates in multiple myeloma: a fractured consensus. *Leukemia and Lymphoma*, **2015**, 56, 553-4	1.9	1
475	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. *Blood Cancer Journal*, **2015**, 5, e364	7	70
474	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. *Blood Cancer Journal*, **2015**, 5, e363	7	26
473	Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS syndrome): a paraneoplastic syndrome. *Oxford Medical Case Reports*, **2015**, 2015, 237-40	0.6	3
472	New cancers after autotransplantations for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 738-45	4.7	28
471	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. *American Journal of Hematology*, **2015**, 90, 181-6	7.1	60
470	Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. *Blood Cancer Journal*, **2015**, 5, e271	7	13
469	Abstract 2653: Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma **2015**,		2
468	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). *Blood*, **2015**, 126, 1774-1774	2.2	5
467	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. *Blood*, **2015**, 126, 1830-1830	2.2	1
466	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 1b Results. *Blood*, **2015**, 126, 3038-3038	2.2	15
465	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. *Blood*, **2015**, 126, 3050-3050	2.2	8
464	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. *Blood*, **2015**, 126, 3177-3177	2.2	3
463	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. *Blood*, **2015**, 126, 4197-4197	2.2	5

462	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. *Blood*, **2015**, 126, 4201-4201	2.2	3
461	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. *Blood*, **2015**, 126, 4219-4219	2.2	10
460	A Dose Finding Phase II Trial of Isatuximab (SAR650984, Anti-CD38 mAb) As a Single Agent in Relapsed/Refractory Multiple Myeloma. *Blood*, **2015**, 126, 509-509	2.2	26
459	Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537). *Blood*, **2015**, 126, 727-727	2.2	26
458	Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).. *Journal of Clinical Oncology*, **2015**, 33, 8576-8576	2.2	5
457	Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 1398-435	7.3	51
456	Clinical outcomes in t(11;14) multiple myeloma.. *Journal of Clinical Oncology*, **2015**, 33, 8592-8592	2.2	
455	Phase III trial of stem cell transplantation compared to melphalan and dexamethasone in the treatment of immunoglobulin light chain amyloidosis (AL).. *Journal of Clinical Oncology*, **2015**, 33, 8595-8595	2.2	
454	Survival trends in young patients with Waldenstrom macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2015**, 33, 8596-8596	2.2	
453	Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors. *Blood*, **2015**, 126, 4249-4249	2.2	
452	Appropriate Dose Adjustment of Dexamethasone Does Not Compromise Outcomes in Relapsed Refractory Multiple Myeloma. *Blood*, **2015**, 126, 1839-1839	2.2	
451	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). *Blood*, **2015**, 126, 3292-3292	2.2	
450	Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study. *Blood*, **2015**, 126, 5322-5322	2.2	
449	Anti-Tumor Phagocytic Cell Activation in Multiple Myeloma By the IAP Antagonist LCL161: Results of a Phase II Clinical Trial. *Blood*, **2015**, 126, 3039-3039	2.2	
448	Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity. *Blood*, **2015**, 126, 634-634	2.2	
447	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 4176-4176	2.2	
446	Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM). *Blood*, **2015**, 126, 2105-2105	2.2	1
445	The Impact of Induction Regimen Choice on Transplant Outcome and Survival in Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. *Blood*, **2015**, 126, 3044-3044	2.2	

444	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. *Cancer Cell*, **2014**, 25, 91-101	24.3	657
443	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncology, The*, **2014**, 15, 333-42	21.7	206
442	Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. *Leukemia*, **2014**, 28, 1122-8	10.7	880
441	Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma. *Leukemia*, **2014**, 28, 455-7	10.7	4
440	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia*, **2014**, 28, 525-42	10.7	179
439	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. *European Journal of Haematology*, **2014**, 92, 485-90	3.8	21
438	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. *Leukemia Research*, **2014**, 38, 1358-66	2.7	10
437	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. *Lancet Haematology,the*, **2014**, 1, e28-e36	14.6	31
436	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncology, The*, **2014**, 15, e538-48	21.7	2253
435	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 356-69	2	6
434	Quantification of clonal circulating plasma cells in relapsed multiple myeloma. *British Journal of Haematology*, **2014**, 167, 500-5	4.5	62
433	Initial treatment of transplant-eligible patients in multiple myeloma. *Expert Review of Hematology*, **2014**, 7, 43-53	2.8	12
432	Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. *Leukemia*, **2014**, 28, 398-403	10.7	45
431	Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratification. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 222-8	4.7	29
430	The clinical significance of cereblon expression in multiple myeloma. *Leukemia Research*, **2014**, 38, 23-8	2.7	72
429	Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. *Blood*, **2014**, 123, 647-9	2.2	30
428	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood*, **2014**, 124, 1047-55	2.2	169
427	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. *Blood*, **2014**, 124, 907-12	2.2	83

426	Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. *Bone Marrow Transplantation*, **2014**, 49, 201-5	4.4	19
425	Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. *Leukemia*, **2014**, 28, 2060-5	10.7	83
424	Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. *Leukemia*, **2014**, 28, 1537-42	10.7	91
423	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. *Leukemia and Lymphoma*, **2014**, 55, 1968-79	1.9	18
422	Risk adapted therapy for multiple myeloma: back to basics. *Leukemia and Lymphoma*, **2014**, 55, 2219-20	1.9	9
421	AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia. *British Journal of Haematology*, **2014**, 164, 352-365	4.5	24
420	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. *American Journal of Hematology*, **2014**, 89, 302-5	7.1	2
419	Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. *Leukemia*, **2014**, 28, 1519-28	10.7	36
418	Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma. *Clinical Transplantation*, **2014**, 28, 1084-91	3.8	15
417	Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. *British Journal of Haematology*, **2014**, 164, 146-50	4.5	17
416	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. *Lancet Oncology, The*, **2014**, 15, 1503-1512	21.7	207
415	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. *American Journal of Hematology*, **2014**, 89, 1051-4	7.1	25
414	Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, S147	2	6
413	Post-transplant therapy in multiple myeloma: a hung jury?. *Lancet Haematology,the*, **2014**, 1, e90-1	14.6	
412	High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. *Heart*, **2014**, 100, 383-8	5.1	52
411	Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. *Mayo Clinic Proceedings*, **2014**, 89, 484-92	6.4	173
410	Early Mortality in Multiple Myeloma: Risk Factors and Impact on Population Outcomes. *Blood*, **2014**, 124, 1320-1320	2.2	4
409	Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing. *Blood*, **2014**, 124, 169-169	2.2	1

408	Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple Myeloma. *Blood*, **2014**, 124, 2053-2053	2.2	1
407	Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma. *Blood*, **2014**, 124, 301-301	2.2	24
406	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). *Blood*, **2014**, 124, 304-304	2.2	24
405	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. *Blood*, **2014**, 124, 3382-3382	2.2	3
404	Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results. *Blood*, **2014**, 124, 82-82	2.2	15
403	Trends in survival of patients with primary plasma cell leukemia: A population-based analysis from 1973 to 2010.. *Journal of Clinical Oncology*, **2014**, 32, 8608-8608	2.2	1
402	Outcomes of young patients with Waldenstrom macroglobulinemia (WM).. *Journal of Clinical Oncology*, **2014**, 32, 8609-8609	2.2	1
401	Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8595-8595	2.2	
400	Outcomes after relapse from first autologous stem cell transplantation in multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8598-8598	2.2	
399	ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCI?Trial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.. *Journal of Clinical Oncology*, **2014**, 32, 8600-8600	2.2	
398	Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy. *Blood*, **2014**, 124, 3456-3456	2.2	
397	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. *Blood*, **2014**, 124, 4780-4780	2.2	
396	Exome Sequencing in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Families Identifies Cosegregating Functional Variants. *Blood*, **2014**, 124, 1967-1967	2.2	
395	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. *Blood*, **2014**, 124, 4751-4751	2.2	
394	Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma. *Blood*, **2014**, 124, 2059-2059	2.2	
393	Overcoming Resistance to Apoptosis in Multiple Myeloma By Simultaneous Inhibition of Bcl2 and IAP Families of Anti-Apoptotic Proteins. *Blood*, **2014**, 124, 2088-2088	2.2	
392	Progression and Outcome in Patients with Biclonal Gammopathies. *Blood*, **2014**, 124, 5699-5699	2.2	
391	Approach to Relapsed Refractory Myeloma **2014**, 95-100		

390	New Agents for Multiple Myeloma **2014**, 131-140		
389	Molecular Classification and Risk Stratification **2014**, 55-64		
388	Treatment of Newly Diagnosed Multiple Myeloma **2014**, 81-94		1
387	Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. *Investigational New Drugs*, **2013**, 31, 1201-6	4.3	17
386	Salvage second hematopoietic cell transplantation in myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 760-6	4.7	87
385	35-year-old man with Fever and abdominal pain. *Mayo Clinic Proceedings*, **2013**, 88, 866-70	6.4	2
384	Smoldering multiple myeloma requiring treatment: time for a new definition?. *Blood*, **2013**, 122, 4172-81	12.2	51
383	Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. *Leukemia*, **2013**, 27, 208-12	10.7	78
382	Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. *Cancer*, **2013**, 119, 4308-15	6.4	12
381	Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. *Gynecologic Oncology*, **2013**, 130, 441-5	4.9	38
380	Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. *European Journal of Haematology*, **2013**, 91, 504-13	3.8	11
379	Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. *Blood Cancer Journal*, **2013**, 3, e143	7	69
378	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. *American Journal of Hematology*, **2013**, 88, 375-8	7.1	28
377	Digging deeper with allogeneic transplantation in multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 335-6	4.7	3
376	Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 87-93	4.7	66
375	Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients. *Leukemia Research*, **2013**, 37, 1527-31	2.7	2
374	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. *Mayo Clinic Proceedings*, **2013**, 88, 360-76	6.4	341
373	Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1395-8	4.7	6

372	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). *Biology of Blood and Marrow Transplantation*, **2013**, 19, S130-S131	4.7	2
371	Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 184-6	2	9
370	Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1233-7	4.7	24
369	Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1615-24	4.7	85
368	Suppression of Involved Immunoglobulin Free Light Chain Post Therapy and Survival Outcomes Following Autologous Stem Cell Transplantation for Myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, S156	4.7	3
367	Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. *Leukemia*, **2013**, 27, 515-6	10.7	15
366	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia*, **2013**, 27, 780-91	10.7	222
365	Second auto-SCT for treatment of relapsed multiple myeloma. *Bone Marrow Transplantation*, **2013**, 48, 568-73	4.4	47
364	Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. *Bone Marrow Transplantation*, **2013**, 48, 1302-7	4.4	58
363	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. *Haematologica*, **2013**, 98, 988-92	6.6	39
362	Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT. *Bone Marrow Transplantation*, **2013**, 48, 1543-7	4.4	24
361	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. *Leukemia*, **2013**, 27, 1738-44	10.7	152
360	Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. *Journal of Clinical Oncology*, **2013**, 31, 4319-24	2.2	146
359	Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. *Clinical Cancer Research*, **2013**, 19, 4816-23	12.9	109
358	Reply to S. Girnius et al. *Journal of Clinical Oncology*, **2013**, 31, 2750-1	2.2	1
357	Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. *Clinical Medicine Insights: Oncology*, **2013**, 7, 53-73	1.8	19
356	Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. *Bone Marrow Transplantation*, **2013**, 48, 557-61	4.4	124
355	Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. *Journal of Clinical Oncology*, **2013**, 31, 4529-35	2.2	122

354	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. *European Journal of Haematology*, **2013**, 91, 193-5	3.8	1
353	Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. *Leukemia*, **2013**, 27, 1391-3	10.7	35
352	A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. *Leukemia*, **2013**, 27, 220-5	10.7	70
351	Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. *Leukemia*, **2013**, 27, 2062-6	10.7	26
350	Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. *Leukemia*, **2013**, 27, 941-6	10.7	158
349	Treatment patterns and outcomes in elderly patients with multiple myeloma. *Leukemia*, **2013**, 27, 971-4	10.7	14
348	High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. *Leukemia*, **2013**, 27, 680-5	10.7	113
347	Outcomes of patients with POEMS syndrome treated initially with radiation. *Blood*, **2013**, 122, 68-73	2.2	54
346	Implications of continued response after autologous stem cell transplantation for multiple myeloma. *Blood*, **2013**, 122, 1746-9	2.2	18
345	Candidate genes of Waldenstrm's macroglobulinemia: current evidence and research. *The Application of Clinical Genetics*, **2013**, 6, 33-42	3.1	4
344	Survival Outcomes Of Very Young (. *Blood*, **2013**, 122, 2136-2136	2.2	1
343	Soluble ST2 (sST2) Is a Novel Valuable Prognostic Marker Among Patients With Immunoglobulin Light Chain (AL) Amyloidosis. *Blood*, **2013**, 122, 3095-3095	2.2	1
342	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. *Blood*, **2013**, 122, 3117-3117	2.2	2
341	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. *Blood*, **2013**, 122, 407-407	2.2	10
340	Newer IMiDs **2013**, 181-213		
339	Development Of Solid Malignancies In Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS): A Population-Based Study Of 17,315 Patients. *Blood*, **2013**, 122, 3134-3134	2.2	
338	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. *Blood*, **2013**, 122, 754-754	2.2	
337	Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels. *Blood*, **2013**, 122, 1962-1962	2.2	

336	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). *Blood*, **2013**, 122, 1854-1854	2.2	
335	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. *Blood*, **2013**, 122, 1842-1842	2.2	
334	Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. *European Journal of Haematology*, **2012**, 89, 228-35	3.8	11
333	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. *British Journal of Haematology*, **2012**, 157, 472-5	4.5	7
332	Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. *Cancer*, **2012**, 118, 1585-92	6.4	92
331	Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. *American Journal of Hematology*, **2012**, 87, 1-4	7.1	13
330	Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis. *American Journal of Hematology*, **2012**, 87, 51-4	7.1	16
329	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. *American Journal of Hematology*, **2012**, 87, 277-83	7.1	20
328	Immunoglobulin D amyloidosis: a distinct entity. *Blood*, **2012**, 119, 44-8	2.2	12
327	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. *Blood*, **2012**, 119, 1117-22	2.2	63
326	Progression in smoldering Waldenstrom macroglobulinemia: long-term results. *Blood*, **2012**, 119, 4462-6	2.2	83
325	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. *Blood*, **2012**, 119, 4860-7	2.2	108
324	Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. *Blood*, **2012**, 120, 56-62	2.2	105
323	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. *Blood*, **2012**, 119, 2100-5	2.2	181
322	New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *Journal of Clinical Oncology*, **2012**, 30, 4541-9	2.2	553
321	MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. *Leukemia*, **2012**, 26, 340-8	10.7	60
320	Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. *Mayo Clinic Proceedings*, **2012**, 87, 517-23	6.4	73
319	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. *Leukemia*, **2012**, 26, 149-57	10.7	580

318	Carfilzomib for myeloma: proteasome inhibition with a different flavor?. *Community Oncology*, **2012**, 9, 270-271		
317	Bortezomib for myeloma: optimizing treatment strategies. *Community Oncology*, **2012**, 9, 272-273		2
316	Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. *Mayo Clinic Proceedings*, **2012**, 87, 1071-9	6.4	71
315	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. *Leukemia*, **2012**, 26, 839-41	10.7	10
314	Trends and outcomes of modern staging of solitary plasmacytoma of bone. *American Journal of Hematology*, **2012**, 87, 647-51	7.1	49
313	Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. *Cancer*, **2012**, 118, 6105-9	6.4	52
312	Clonal competition with alternating dominance in multiple myeloma. *Blood*, **2012**, 120, 1067-76	2.2	473
311	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. *British Journal of Haematology*, **2012**, 156, 326-33	4.5	45
310	Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *Journal of Clinical Oncology*, **2012**, 30, 989-95	2.2	582
309	Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. *Nephrology Dialysis Transplantation*, **2012**, 27, 1097-101	4.3	47
308	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. *Blood*, **2012**, 119, 4375-82	2.2	335
307	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. *Leukemia*, **2012**, 26, 1091-7	10.7	67
306	Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies. *Leukemia*, **2012**, 26, 1119-22	10.7	12
305	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. *Blood*, **2012**, 119, 5397-404	2.2	125
304	Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 1964-8	6.9	56
303	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. *Blood*, **2012**, 120, 194-194	2.2	9
302	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients. *Blood*, **2012**, 120, 201-201	2.2	15
301	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. *Blood*, **2012**, 120, 3138-3138	2.2	20

300	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). *Blood*, **2012**, 120, 332-332	2.2	12
299	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. *Blood*, **2012**, 120, 3972-3972	2.2	6
298	Cost Effectiveness Decision Tree Analysis of Early Versus Late Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) in the United States (US). *Blood*, **2012**, 120, 602-602	2.2	1
297	Phase 1/2 Trial of a Novel CDK Inhibitor Dinaciclib (SCH727965) in Patients with Relapsed Multiple Myeloma Demonstrates Encouraging Single Agent Activity. *Blood*, **2012**, 120, 76-76	2.2	2
296	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. *Blood*, **2012** , 120, 946-946	2.2	1
295	Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study.. *Journal of Clinical Oncology*, **2012**, 30, 8095-8095	2.2	8
294	Cell Trafficking in Multiple Myeloma. *Open Journal of Hematology*, **2012**, 3,		8
293	Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. *PLoS ONE*, **2012**, 7, e50005	3.7	45
292	Does stage migration exist in active multiple myeloma (MM)?. *Journal of Clinical Oncology*, **2012**, 30, 8105-8105	2.2	
291	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. *Blood*, **2012**, 120, 2973-2973	2.2	
290	Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.. *Blood*, **2012**, 120, 2948-2948	2.2	
289	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. *Blood*, **2012**, 120, 934-934	2.2	
288	Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.. *Blood*, **2012**, 120, 2943-2943	2.2	
287	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. *Blood*, **2012**, 120, 2059-2059	2.2	
286	Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. *Mayo Clinic Proceedings*, **2011**, 86, 12-8	6.4	141
285	Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1129-36	12.7	144
284	IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrm's macroglobulinemia (SWM). *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 74-6	2	20
283	Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. *Bone Marrow Transplantation*, **2011**, 46, 970-5	4.4	54

282	Cardiac amyloidosis: a practical approach to diagnosis and management. *American Journal of Medicine*, **2011**, 124, 1006-15	2.4	73
281	A Cost Effective Analysis of a Risk-Adapted Algorithm for Plerixafor Use in Autologous Peripheral Blood Stem Cell Mobilization. *Biology of Blood and Marrow Transplantation*, **2011**, 17, S159-S160	4.7	5
280	Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. *Therapy: Open Access in Clinical Medicine*, **2011**, 8, 415-429		3
279	Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. *Blood*, **2011**, 118, 1979-88	2.2	69
278	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*, **2011**, 118, 4359-62	2.2	33
277	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood*, **2011**, 118, 2970-5	2.2	170
276	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. *Blood*, **2011**, 118, 1763-5	2.2	53
275	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1□levels in patients with MGUS. *Blood*, **2011**, 118, 6529-34	2.2	55
274	The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. *Blood*, **2011**, 118, 4663-5	2.2	133
273	Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. *British Journal of Haematology*, **2011**, 155, 340-8	4.5	26
272	Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. *Leukemia*, **2011**, 25, 689-96	10.7	94
271	Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. *Leukemia*, **2011**, 25, 906-8	10.7	131
270	Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. *Leukemia*, **2011**, 25, 1195-7	10.7	7
269	Outcome assessment following treatment of isolated lymphatic recurrences in patients with endometrial cancer. *Gynecologic Oncology*, **2011**, 120, S91	4.9	2
268	SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. *Bone Marrow Transplantation*, **2011**, 46, 956-61	4.4	12
267	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. *Annals of Hematology*, **2011**, 90, 101-6	3	32
266	Treatment of newly diagnosed multiple myeloma in transplant-eligible patients. *Current Hematologic Malignancy Reports*, **2011**, 6, 104-12	4.4	9
265	Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. *American Journal of Hematology*, **2011**, 86, 251-5	7.1	74

264	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. *American Journal of Hematology*, **2011**, 86, 640-5	7.1	51
263	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood*, **2011**, 117, 4701-5	2.2	323
262	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. *Blood*, **2011**, 118, 2985-7	2.2	27
261	Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. *Nephrology Dialysis Transplantation*, **2011**, 26, 2032-6	4.3	72
260	Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. *Molecular Therapy*, **2011**, 19, 1034-40	11.7	21
259	Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. *Bone Marrow Transplantation*, **2011**, 46, 291-3	4.4	5
258	Trend toward improved day 100 and two-year survival following stem cell transplantation for AL: a comparison before and after 2006. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2011**, 18 Suppl 1, 137-8	2.7	4
257	Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. *Bone Marrow Transplantation*, **2011**, 46, 943-9	4.4	50
256	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. *Blood*, **2011**, 118, 2887-2887	2.2	1
255	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. *Blood*, **2011**, 118, 2942-2942	2.2	2
254	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. *Blood*, **2011**, 118, 2950-2950	2.2	1
253	Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745.. *Journal of Clinical Oncology*, **2011**, 29, 4116-4116	2.2	2
252	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. *Blood*, **2011**, 118, 2945-2945	2.2	
251	Generation of An Automated Tool for the Identification of Genetics Markers and Signatures in Multiple Myeloma Risk-Stratification. *Blood*, **2011**, 118, 2881-2881	2.2	
250	Relapse of POEMS Following Autologous Stem Cell Transplantation: A Single Center Experience. *Blood*, **2011**, 118, 3101-3101	2.2	
249	Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy. *Blood*, **2011**, 118, 2992-2992	2.2	
248	The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis. *Blood*, **2011**, 118, 2868-2868	2.2	
247	Racial Disparities in Cytogenetic Characteristics and Outcome of Multiple Myeloma. *Blood*, **2011**, 118, 1808-1808	2.2	

246	Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. *Oncology*, **2011**, 25 Suppl 2, 32-43	1.8	2
245	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. *British Journal of Haematology*, **2010**, 148, 853-8	4.5	2
244	Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. *Oncogene*, **2010**, 29, 1190-202	9.2	77
243	Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. *Leukemia*, **2010**, 24, 1350-6	10.7	68
242	Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. *Leukemia*, **2010**, 24, 1498-505	10.7	30
241	Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). *Leukemia*, **2010**, 24, 1934-9	10.7	166
240	Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. *Nephrology Dialysis Transplantation*, **2010**, 25, 1340-3	4.3	35
239	Stem cell transplantation in patients with autonomic neuropathy due to primary (AL) amyloidosis. *Neurology*, **2010**, 74, 913-8	6.5	25
238	Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. *Mayo Clinic Proceedings*, **2010**, 85, 905-12	6.4	96
237	Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. *Mayo Clinic Proceedings*, **2010**, 85, 232-8	6.4	49
236	Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. *Mayo Clinic Proceedings*, **2010**, 85, 532-7	6.4	52
235	Conflicts of interest, authorship, and disclosures in industry-related scientific publications. *Mayo Clinic Proceedings*, **2010**, 85, 197-9; author reply 201-4	6.4	2
234	Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. *Leukemia and Lymphoma*, **2010**, 51, 2181-7	1.9	92
233	Immunophenotyping in multiple myeloma and related plasma cell disorders. *Best Practice and Research in Clinical Haematology*, **2010**, 23, 433-51	4.2	78
232	A Risk Adapted Approach Utilizing Plerixafor In Autologous Peripheral Blood Stem Cell Mobilization. *Biology of Blood and Marrow Transplantation*, **2010**, 16, S197-S198	4.7	10
231	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. *Biology of*	4.7	85
230	Diagnosis and management of Waldenstrm macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. *Mayo Clinic Proceedings*, **2010**, 85, 824-33	6.4	119
229	Multiple myeloma - current issues and controversies. *Cancer Treatment Reviews*, **2010**, 36 Suppl 2, S3-11	14.4	35

228	Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. *Clinical Lymphoma, Myeloma and Leukemia* , **2010**, 10, 458-63	2	22
227	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. *Lancet, The*, **2010**, 375, 1721-8	40	249
226	Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. *Blood*, **2010**, 115, 2348-53; quiz 2560	2.2	37
225	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. *Blood*, **2010**, 115, 1343-50	2.2	103
224	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. *Blood*, **2010**, 116, 2019-25; quiz 2197	2.2	46
223	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. *Blood*, **2010**, 116, 5126-9	2.2	125
222	Treatment of newly diagnosed multiple myeloma: advances in current therapy. *Medical Oncology*, **2010**, 27 Suppl 1, S14-24	3.7	9
221	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. *European Journal of Haematology*, **2010**, 85, 200-8	3.8	8
220	Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. *Cancer*, **2010**, 116, 640-6	6.4	2
219	A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. *American Journal of Hematology*, **2010**, 85, 409-13	7.1	13
218	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. *American Journal of Hematology*, **2010**, 85, 431-4	7.1	31
217	Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. *American Journal of Hematology*, **2010**, 85, 664-9	7.1	46
216	TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. *American Journal of Hematology*, **2010**, 85, 675-86	7.1	47
215	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. *American Journal of Hematology*, **2010**, 85, 737-40	7.1	17
214	Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. *American Journal of Hematology*, **2010**, 85, 757-9	7.1	96
213	Current Therapies for Light-Chain Amyloidosis **2010**, 775-793		
212	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. *Blood*, **2010**, 116, 1893-1893	2.2	1
211	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. *Blood*, **2010**, 116, 1964-1964	2.2	5

210	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). *Blood*, **2010**, 116, 3053-3053	2.2	1
209	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. *Blood*, **2010**, 116, 370-370	2.2	4
208	Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival. *Blood*, **2010**, 116, 3893-3893	2.2	2
207	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. *Blood*, **2010**, 116, 621-621	2.2	9
206	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. *Blood*, **2010**, 116, 863-863	2.2	1
205	NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.. *Journal of Clinical Oncology*, **2010**, 28, 2018-2018	2.2	3
204	A phase II study of pomalidomide and dexamethasone in previously treated light-chain (AL) amyloidosis.. *Journal of Clinical Oncology*, **2010**, 28, 8025-8025	2.2	2
203	A comparison of lenalidomide/dexamethasone (RD) versus cyclophosphamide/lenalidomide/dexamethasone (CRD) versus cyclophosphamide/bortezomib/dexamethasone (CyborD) in newly diagnosed multiple myeloma (MM).. *Journal of Clinical Oncology*, **2010**, 28, 8131-8131	2.2	3
202	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. *Blood*, **2010**, 116, 1965-1965	2.2	
201	Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches. *Blood*, **2010**, 116, 2253-2253	2.2	
200	Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines. *Blood*, **2010**, 116, 3014-3014	2.2	
199	Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma. *Blood*, **2010**, 116, 4078-4078	2.2	
198	Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma. *Blood*, **2010**, 116, 2998-2998	2.2	
197	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood*, **2009**, 113, 5412-7	2.2	714
196	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. *Nephrology Dialysis Transplantation*, **2009**, 24, 3132-7	4.3	85
195	Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *Journal of Clinical Oncology*, **2009**, 27, 5008-14	2.2	252
194	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell*, **2009**, 16, 309-23	24.3	197
193	Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. *American Journal of Hematology*, **2009**, 84, 397-400	7.1	46

192	Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. *American Journal of Hematology*, **2009**, 84, 401-7	7.1	46
191	Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. *American Journal of Hematology*, **2009**, 84, 799-802	7.1	71
190	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. *British Journal of Haematology*, **2009**, 146, 164-70	4.5	71
189	Dexamethasone and the risk for adrenal suppression in multiple myeloma. *Leukemia*, **2009**, 23, 1009-11	10.7	7
188	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia*, **2009**, 23, 1716-30	10.7	123
187	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, **2009**, 23, 1904-12	10.7	170
186	International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. *Leukemia*, **2009**, 23, 1545-56	10.7	356
185	Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. *Bone Marrow Transplantation*, **2009**, 43, 619-25	4.4	95
184	Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma. *Leukemia and Lymphoma*, **2009**, 50, 1033-5	1.9	
183	Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leukemia and Lymphoma*, **2009**, 50, 781-7	1.9	5
182	Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood*, **2009**, 114, 1729-35	2.2	170
181	Antiangiogenic Agents in Multiple Myeloma. *Clinical Lymphoma and Myeloma*, **2009**, 9, S44-S45		
180	Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma. *Clinical Lymphoma and Myeloma*, **2009**, 9, S46-S47		1
179	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. *Mayo Clinic Proceedings*, **2009**, 84, 1095-110	6.4	199
178	Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. *Mayo Clinic Proceedings*, **2009**, 84, 114-22	6.4	211
177	Stem cell transplantation for multiple myeloma. *Current Opinion in Oncology*, **2009**, 21, 162-70	4.2	14
176	The significance of monoclonal gammopathy of undetermined significance. *Haematologica*, **2009**, 94, 1641-4	6.6	21
175	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*, **2009**, 114, 785-90	2.2	101

174	The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma. *Blood*, **2009**, 114, 2617-8	2.2	35
173	Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. *Blood*, **2009**, 114, 518-21	2.2	118
172	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. *Blood*, **2009**, 114, 2926-35	2.2	139
171	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. *Haematologica*, **2009**, 94, 380-6	6.6	80
170	Novel Three and Four Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. *Blood*, **2009**, 114, 127-127	2.2	11
169	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. *Blood*, **2009**, 114, 3853-3853	2.2	6
168	A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.. *Blood*, **2009**, 114, 3854-3854	2.2	1
167	Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 2005.. *Blood*, **2009**, 114, 54-54	2.2	5
166	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.. *Blood*, **2009**, 114, 615-615	2.2	2
165	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. *Blood*, **2009**, 114, 956-956	2.2	1
164	Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM). *Journal of Clinical Oncology*, **2009**, 27, 8587-8587	2.2	
163	Natural history of multiple myeloma (MM) relapsing after autologous stem cell transplantation (ASCT). *Journal of Clinical Oncology*, **2009**, 27, e19513-e19513	2.2	
162	Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization. *Journal of Clinical Oncology*, **2009**, 27, 7039-7039	2.2	
161	Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma. *Journal of Clinical Oncology*, **2009**, 27, 8603-8603	2.2	
160	Review: extramedullary disease in multiple myeloma. *Clinical Advances in Hematology and Oncology*, **2009**, 7, 802-4	0.6	11
159	Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. *Leukemia*, **2008**, 22, 1933-7	10.7	120
158	Impact of additional cytoreduction following autologous SCT in multiple myeloma. *Bone Marrow Transplantation*, **2008**, 42, 259-64	4.4	9
157	Impact of early relapse after auto-SCT for multiple myeloma. *Bone Marrow Transplantation*, **2008**, 42, 413-20	4.4	68

156	Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. *Bone Marrow Transplantation*, **2008**, 41, 1013-9	4.4	17
155	Reply to Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients *Leukemia*, **2008**, 22, 1281-1282	10.7	32
154	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. *British Journal of Haematology*, **2008**, 141, 205-11	4.5	17
153	Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. *British Journal of Haematology*, **2008**, 141, 792-8	4.5	58
152	R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. *Experimental Hematology*, **2008**, 36, 568-76	3.1	47
151	Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. *European Journal of Haematology*, **2008**, 80, 397-406	3.8	104
150	Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. *Mayo Clinic Proceedings*, **2008**, 83, 1131-8	6.4	83
149	Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. *Journal of Heart and Lung Transplantation*, **2008**, 27, 823-9	5.8	96
148	Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. *Clinical Cancer Research*, **2008**, 14, 3503-13	12.9	31
147	94: Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 36-37	4.7	49
146	Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 1134-1140	4.7	22
145	Serum uric acid: novel prognostic factor in primary systemic amyloidosis. *Mayo Clinic Proceedings*, **2008**, 83, 297-303	6.4	32
144	Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. *Kidney International*, **2008**, 73, 1282-8	9.9	140
143	Fabrication of Gold Nanoparticle for Potential Application in Multiple Myeloma. *Journal of Biomedical Nanotechnology*, **2008**, 4, 499-507	4	8
142	Improved survival in multiple myeloma and the impact of novel therapies. *Blood*, **2008**, 111, 2516-20	2.2	1753
141	Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. *Leukemia and Lymphoma*, **2008**, 49, 36-41	1.9	68
140	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood*, **2008**, 111, 785-9	2.2	293
139	Many facets of bortezomib resistance/susceptibility. *Blood*, **2008**, 112, 2177-8	2.2	69

138	Role of allogeneic stem cell transplantation in multiple myeloma. *Current Hematologic Malignancy Reports*, **2008**, 3, 99-106	4.4	3
137	Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrm's macroglobulinemia. *Clinical and Experimental Nephrology*, **2008**, 12, 292-295	2.5	15
136	Malignant primary cardiac tumors: review of a single institution experience. *Cancer*, **2008**, 112, 2440-6	6.4	210
135	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. *American Journal of Hematology*, **2008**, 83, 614-7	7.1	110
134	Solitary plasmacytoma: is radiation therapy sufficient?. *American Journal of Hematology*, **2008**, 83, 695-6	7.1	22
133	A novel report of cig-FISH and cytogenetics in POEMS syndrome. *American Journal of Hematology*, **2008**, 83, 840-1	7.1	12
132	High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. *New England Journal of Medicine*, **2008**, 358, 91; author reply 92-3	59.2	35
131	Normalization of the Serum Free Light Chain (FLC) Ratio Is Associated with Superior Overall Survival among Myeloma Patients Achieving Immunofixation Negative State: Results Support Incorporation of Serum FLC Ratio in Stringent CR Definition.. *Blood*, **2008**, 112, 1692-1692	2.2	5
130	Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2008**, 112, 3467-3467	2.2	2
129	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma. *Blood*, **2008**, 112, 866-866	2.2	6
128	Phase II Trial of Lenalidomide (Revlimid) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma. *Blood*, **2008**, 112, 91-91	2.2	7
127	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. *Blood*, **2008**, 112, 93-93	2.2	12
126	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. *Blood*, **2008**, 112, 95-95	2.2	1
125	A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. *Journal of Clinical Oncology*, **2008**, 26, 2569-2569	2.2	2
124	High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma. *Journal of Clinical Oncology*, **2008**, 26, 8586-8586	2.2	2
123	Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma **2008**, 279-288		
122	Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features. *Blood*, **2008**, 112, 2733-2733	2.2	
121	Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. *Blood*, **2008**, 112, 2769-2769	2.2	

120	Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. *Mayo Clinic Proceedings*, **2007**, 82, 1179-84	6.4	133
119	Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. *Mayo Clinic Proceedings*, **2007**, 82, 323-41	6.4	123
118	Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells. *Advanced Materials*, **2007**, 19, 711-716	24	80
117	Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. *Leukemia Research*, **2007**, 31, 591-8	2.7	54
116	Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. *Bone Marrow Transplantation*, **2007**, 39, 605-11	4.4	50
115	Autologous stem cell transplantation in the elderly including pre- and post-treatment options. *Bone Marrow Transplantation*, **2007**, 40, 1115-21	4.4	2
114	Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). *Bone Marrow Transplantation*, **2007**, 40, 989-93	4.4	10
113	A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. *Leukemia*, **2007**, 21, 529-34	10.7	168
112	Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. *Leukemia*, **2007**, 21, 2043-6	10.7	54
111	ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. *Leukemia*, **2007**, 21, 1549-60	10.7	131
110	Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia*, **2007**, 21, 2035-42	10.7	270
109	In vivo and in silico studies on single versus multiple transplants for multiple myeloma. *Cancer Science*, **2007**, 98, 734-9	6.9	6
108	Serum M-spike and transplant outcome in patients with multiple myeloma. *Cancer Science*, **2007**, 98, 1035-40	6.9	12
107	Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell*, **2007**, 12, 131-44	24.3	832
106	Role of autologous stem cell transplantation in multiple myeloma. *Current Hematologic Malignancy Reports*, **2007**, 2, 121-7	4.4	
105	Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. *Cancer Research*, **2007**, 67, 2982-9	10.1	192
104	Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clinical Cancer Research*, **2007**, 13, 5903-9	12.9	116
103	Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. *Journal of Biological Chemistry*, **2007**, 282, 29831-46	5.4	95

102	Relationship between depth of response and outcome in multiple myeloma. *Journal of Clinical Oncology*, **2007**, 25, 4933-7	2.2	38
101	Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2007**, 2, 440-4	6.9	32
100	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. *Blood*, **2007**, 109, 465-70	2.2	228
99	Transplantation for amyloidosis. *Current Opinion in Oncology*, **2007**, 19, 136-41	4.2	72
98	Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. *Mayo Clinic Proceedings*, **2007**, 82, 323-341	6.4	119
97	Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. *Haematologica*, **2007**, 92, 1415-8	6.6	102
96	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. *Blood*, **2007**, 110, 1487-1487	2.2	1
95	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. *Blood*, **2007**, 110, 190-190	2.2	6
94	Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?.. *Blood*, **2007**, 110, 939-939	2.2	1
93	Outcome after second stem cell transplantation for relapsed multiple myeloma. *Journal of Clinical Oncology*, **2007**, 25, 8118-8118	2.2	2
92	Outcome of patients relapsing early after autologous stem cell transplantation for multiple myeloma. *Journal of Clinical Oncology*, **2007**, 25, 8022-8022	2.2	
91	Prevention of active multiple myeloma (MM) using IL-1 receptor antagonist (IL-1ra) and low-dose dexamethasone (Dex) and monitoring the high sensitivity C-reactive protein (hsCRP). *Journal of Clinical Oncology*, **2007**, 25, 8105-8105	2.2	
90	Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00).. *Blood*, **2007**, 110, 2734-2734	2.2	1
89	Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceeding Plasma Cell Disorders.. *Blood*, **2007**, 110, 945-945	2.2	
88	High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. *Expert Review of Anticancer Therapy*, **2006**, 6, 343-60	3.5	20
87	Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Research*, **2006**, 66, 184-91	10.1	245
86	Progress in the treatment of multiple myeloma. *Lancet, The*, **2006**, 367, 791-2	40	7
85	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 19478-83	11.5	168

84	Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. *Mayo Clinic Proceedings*, **2006**, 81, 1047-53	6.4	193
83	Response to rituximab in patients with type II cryoglobulinemia. *Clinical Lymphoma and Myeloma*, **2006**, 7, 140-4		23
82	Thalidomide and lenalidomide in the treatment of multiple myeloma. *European Journal of Cancer*, **2006**, 42, 1612-22	7.5	97
81	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood*, **2006**, 107, 3378-83	2.2	198
80	Clinical implication of centrosome amplification in plasma cell neoplasm. *Blood*, **2006**, 107, 3669-75	2.2	79
79	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. *British Journal of Haematology*, **2006**, 132, 698-704	4.5	3
78	Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. *British Journal of Haematology*, **2006**, 135, 52-61	4.5	18
77	Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma. *Leukemia*, **2006**, 20, 1863-9	10.7	19
76	High Incidence of IgH Translocations in Monoclonal Gammopathies with Abnormal Free Light Chain Levels.. *Blood*, **2006**, 108, 3514-3514	2.2	3
75	Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, and Survival.. *Blood*, **2006**, 108, 798-798	2.2	23
74	Correlation of bone marrow angiogenesis and response to thalidomide dexamethasone in multiple myeloma. *Journal of Clinical Oncology*, **2006**, 24, 7621-7621	2.2	1
73	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. *Blood*, **2006**, 108, 3500-3500	2.2	
72	Thymoglobulin (Polyclonal Rabbit Anti Thymocyte Globulin) Has In Vivo Activity in a Mouse Model of Myeloma.. *Blood*, **2006**, 108, 3487-3487	2.2	
71	Epigallocatechin-3-Gallate (EGCG), a Polyphenol Extracted from Green Tea, Has Significant In Vitro Activity Against Myeloma Cells.. *Blood*, **2006**, 108, 3465-3465	2.2	
70	Apoptosis Rates in Myeloma Cells Can Be Significantly Affected by CD138 Sorting and by the Specific Method Used To Detect Apoptotic Cells.. *Blood*, **2006**, 108, 3442-3442	2.2	
69	Mi-63, a Small Molecule Inhibitor of MDM2-p53 Interaction, Has Significant In Vitro Activity in Multiple Myeloma.. *Blood*, **2006**, 108, 3464-3464	2.2	
68	Phenotypic Characterization of the CD45+ and CD45− Plasma Cell Compartments in Monoclonal Gammopathies.. *Blood*, **2006**, 108, 3505-3505	2.2	0
67	Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. *Haematologica*, **2006**, 91, 1033-40	6.6	21

66	Thalidomide and dexamethasone: therapy for multiple myeloma. *Expert Review of Anticancer Therapy*, **2005**, 5, 759-66	3.5	21
65	Plasma cell labeling index. *Methods in Molecular Medicine*, **2005**, 113, 25-35		23
64	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. *Blood*, **2005**, 106, 1042-7	2.2	152
63	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. *Blood*, **2005**, 106, 706-12	2.2	52
62	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. *Blood*, **2005**, 106, 4050-3	2.2	541
61	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. *Blood*, **2005**, 105, 4470-6	2.2	54
60	Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. *Archives of Dermatology*, **2005**, 141, 1277-82		46
59	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. *British Journal of Haematology*, **2005**, 128, 192-203	4.5	265
58	Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. *Leukemia*, **2005**, 19, 1253-61	10.7	32
57	CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. *Leukemia*, **2005**, 19, 1466-70	10.7	65
56	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. *Oncogene*, **2005**, 24, 3121-9	9.2	39
55	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. *Oncogene*, **2005**, 24, 5888-96	9.2	54
54	Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *Journal of Clinical Oncology*, **2005**, 23, 5668-74	2.2	93
53	Drug insight: thalidomide as a treatment for multiple myeloma. *Nature Clinical Practice Oncology*, **2005**, 2, 262-70		29
52	Baseline Serum Albumin and Proteinuria Predict Renal Response after Autologous Stem Cell Transplantation in AL Amyloidosis.. *Blood*, **2005**, 106, 1166-1166	2.2	1
51	Thalidomid: current role in the treatment of non-plasma cell malignancies. *Journal of Clinical Oncology*, **2004**, 22, 2477-88	2.2	78
50	High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. *Bone Marrow Transplantation*, **2004**, 34, 161-7	4.4	73
49	Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. *Bone Marrow Transplantation*, **2004**, 34, 235-9	4.4	55

48	Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. *Bone Marrow Transplantation*, **2004**, 34, 485-90	4.4	48
47	Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. *Leukemia*, **2004**, 18, 624-7	10.7	79
46	Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments. *American Journal of Hematology*, **2004**, 77, 7-11	7.1	18
45	Clinical course of patients with relapsed multiple myeloma. *Mayo Clinic Proceedings*, **2004**, 79, 867-74	6.4	266
44	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. *Blood*, **2004**, 104, 1159-65	2.2	123
43	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. *Blood*, **2004**, 104, 2886-92	2.2	130
42	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. *Blood*, **2004**, 104, 4188-93	2.2	167
41	Clinical and Biological Correlates of CD45 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma.. *Blood*, **2004**, 104, 3362-3362	2.2	
40	Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.. *Blood*, **2004**, 104, 2351-2351	2.2	
39	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. *Blood*, **2004**, 104, 928-928	2.2	
38	Combination of the mTOR Inhibitor Rapamycin and Revlimid (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. *Blood*, **2004**, 104, 1492-1492	2.2	1
37	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. *Blood*, **2004**, 104, 2354-2354	2.2	
36	An oncolytic measles virus engineered to enter cells through the CD20 antigen. *Molecular Therapy*, **2003**, 7, 62-72	11.7	76
35	Acute superior mesenteric venous thrombosis: one disease or two?. *American Journal of Gastroenterology*, **2003**, 98, 1299-304	0.7	80
34	Prognostic value of angiogenesis in solitary bone plasmacytoma. *Blood*, **2003**, 101, 1715-7	2.2	86
33	Expression of CD52 on plasma cells in plasma cell proliferative disorders. *Blood*, **2003**, 102, 1075-7	2.2	39
32	Treatment advances in adult immune thrombocytopenic purpura. *Annals of Hematology*, **2003**, 82, 723-37	3	16
31	Acquired von Willebrand's syndrome: a single institution experience. *American Journal of Hematology*, **2003**, 72, 243-7	7.1	60

30	Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. *British Journal of Haematology*, **2003**, 122, 272-4	4.5	21
29	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. *British Journal of Haematology*, **2003**, 123, 305-8	4.5	26
28	Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. *Bone Marrow Transplantation*, **2003**, 32, 1065-9	4.4	4
27	Thalidomide as initial therapy for early-stage myeloma. *Leukemia*, **2003**, 17, 775-9	10.7	200
26	Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. *Leukemia*, **2003**, 17, 1865-70	10.7	77
25	Expression of VEGF and its receptors by myeloma cells. *Leukemia*, **2003**, 17, 2025-31	10.7	118
24	Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. *Mayo Clinic Proceedings*, **2003**, 78, 589-98	6.4	176
23	Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. *Mayo Clinic Proceedings*, **2003**, 78, 34-9	6.4	111
22	Thalidomide as an anti-cancer agent. *Journal of Cellular and Molecular Medicine*, **2002**, 6, 160-74	5.6	51
21	Agnogenic myeloid metaplasia associated with Klinefelter syndrome: a case report. *Annals of Hematology*, **2002**, 81, 215-8	3	12
20	Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses. *Annals of Hematology*, **2002**, 81, 312-9	3	84
19	Bone marrow angiogenesis in multiple myeloma: effect of therapy. *British Journal of Haematology*, **2002**, 119, 665-71	4.5	42
18	Cutaneous and systemic amyloidoses. *International Journal of Dermatology*, **2002**, 41, 133-134	1.7	10
17	Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. *Bone Marrow Transplantation*, **2002**, 30, 161-5	4.4	29
16	Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. *Leukemia*, **2002**, 16, 1311-8	10.7	98
15	Spontaneous pneumomediastinum and subcutaneous emphysema complicating bronchiolitis obliterans after allogeneic bone marrow transplantation--case report and review of literature. *Annals of Hematology*, **2001**, 80, 430-5	3	29
14	High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. *Bone Marrow Transplantation*, **2001**, 28, 381-5	4.4	36
13	Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. *Bone Marrow Transplantation*, **2001**, 28, 951-6	4.4	43

12	Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2001**, 28, 997-9	4.4	15
11	A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1)). *Bone Marrow Transplantation*, **2001**, 28, 1176-7	4.4	7
10	Mesenteric venous thrombosis. *New England Journal of Medicine*, **2001**, 345, 1683-8	59.2	412
9	Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2001**, 27, 1299-303	4.4	94
8	Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease. *Bone Marrow Transplantation*, **2001**, 27, 1133-40	4.4	7
7	59-year-old man with pelvic pain and hypergammaglobulinemia. *Mayo Clinic Proceedings*, **2001**, 76, 311-4	6.4	
6	Hazards of quality-of-life data for clinical decision making. *Journal of Clinical Oncology*, **2001**, 19, 594-5	2.2	2
5	On appetite and its loss. *Journal of Clinical Oncology*, **2000**, 18, 2930-2	2.2	43
4	Hypercalcemia complicating leukemic transformation of agnogenic myeloid metaplasia-myelofibrosis. *Mayo Clinic Proceedings*, **1999**, 74, 1233-7	6.4	11
3	Multiple Myeloma: Molecular Biology, Diagnosis and Treatment315-341		
2	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2
1	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*,	10.7	49